TuHURA Biosciences (HURA) Long-Term Debt Issuances (2020 - 2025)
TuHURA Biosciences (HURA) posted quarterly Long-Term Debt Issuances of $2.9 million for Q4 2025, down 89.84% quarter-over-quarter from $28.6 million in Q3 2024.
TuHURA Biosciences (HURA) Long-Term Debt Issuances (2020 - 2025) Analysis & Trends
TuHURA Biosciences' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $2.9 million for Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $55.4 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, down 89.5% from the prior year.
- Long-Term Debt Issuances for Q4 2025 stood at $2.9 million, down from $28.6 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $28.6 million in Q3 2024, with the low at $2.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.90 Mn |
| Dec 31, 2025 | 2.90 Mn |
| Sep 30, 2024 | 28.57 Mn |
| Sep 30, 2024 | 28.57 Mn |
| Jun 30, 2024 | 19.07 Mn |
| Jun 30, 2024 | 19.07 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Mar 31, 2024 | 4.90 Mn |
| Sep 30, 2020 | 500,000.00 |
| Sep 30, 2020 | 500,000.00 |